VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Phone646 650 1351
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees37
OptionableNot Optionable
VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions
What is VolitionRX's stock symbol?
VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."
How were VolitionRX's earnings last quarter?
VolitionRX Ltd (NYSEAMERICAN:VNRX) posted its quarterly earnings results on Wednesday, November, 7th. The medical research company reported ($0.14) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.14). View VolitionRX's Earnings History.
When is VolitionRX's next earnings date?
What price target have analysts set for VNRX?
4 equities research analysts have issued 1-year target prices for VolitionRX's stock. Their forecasts range from $5.00 to $10.00. On average, they expect VolitionRX's share price to reach $6.50 in the next year. This suggests a possible upside of 155.9% from the stock's current price. View Analyst Price Targets for VolitionRX.
What is the consensus analysts' recommendation for VolitionRX?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.
Has VolitionRX been receiving favorable news coverage?
News stories about VNRX stock have trended very positive on Tuesday, according to InfoTrie. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. VolitionRX earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Are investors shorting VolitionRX?
VolitionRX saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 327,999 shares, an increase of 80.3% from the December 14th total of 181,885 shares. Based on an average daily volume of 113,840 shares, the days-to-cover ratio is presently 2.9 days. Currently, 1.5% of the company's stock are sold short. View VolitionRX's Current Options Chain.
Who are some of VolitionRX's key competitors?
Who are VolitionRX's key executives?
VolitionRX's management team includes the folowing people:
- Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
- Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
- Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
- Dr. Jason Bradley Terrell, Chief Medical Officer & CEO of Volition America Inc. (Age 39)
- Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)
How do I buy shares of VolitionRX?
Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VolitionRX's stock price today?
One share of VNRX stock can currently be purchased for approximately $2.54.
What is VolitionRX's official website?
How can I contact VolitionRX?
The medical research company can be reached via phone at 646 650 1351.
MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
